Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent

Abiodun D. Ogunniyi, Manouchehr Khazandi, Andrew J. Stevens, Sarah K. Sims, Stephen W. Page, Sanjay Garg, Henrietta Venter, Andrew Powell, Karen White, Kiro R. Petrovski, Geraldine Laven-Law, Eliane G. Tótoli, Hérida R. Salgado, Hongfei Pi, Geoffrey W. Coombs, Dean L. Shinabarger, John D. Turnidge, James C. Paton, Adam McCluskey, Darren J. Trott

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The spread of multidrug resistance among bacterial pathogens poses a serious threat to public health worldwide. Recent approaches towards combating antimicrobial resistance include repurposing old compounds with known safety and development pathways as new antibacterial classes with novel mechanisms of action. Here we show that an analog of the anticoccidial drug robenidine (4,6-bis(2-((E)-4-methylbenzylidene)hydrazinyl)pyrimidin-2-amine; NCL195) displays potent bactericidal activity against Streptococcus pneumoniae and Staphylococcus aureus by disrupting the cell membrane potential. NCL195 was less cytotoxic to mammalian cell lines than the parent compound, showed low metabolic degradation rates by human and mouse liver microsomes, and exhibited high plasma concentration and low plasma clearance rates in mice. NCL195 was bactericidal against Acinetobacter spp and Neisseria meningitidis and also demonstrated potent activity against A. baumannii, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Enterobacter spp. in the presence of sub-inhibitory concentrations of ethylenediaminetetra-acetic acid (EDTA) and polymyxin B. These findings demonstrate that NCL195 represents a new chemical lead for further medicinal chemistry and pharmaceutical development to enhance potency, solubility and selectivity against serious bacterial pathogens.

Original languageEnglish
Article numbere0183457
Number of pages23
JournalPLoS ONE
Volume12
Issue number9
DOIs
Publication statusPublished - 1 Sep 2017

Cite this

Ogunniyi, A. D., Khazandi, M., Stevens, A. J., Sims, S. K., Page, S. W., Garg, S., ... Trott, D. J. (2017). Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent. PLoS ONE, 12(9), [e0183457]. https://doi.org/10.1371/journal.pone.0183457
Ogunniyi, Abiodun D. ; Khazandi, Manouchehr ; Stevens, Andrew J. ; Sims, Sarah K. ; Page, Stephen W. ; Garg, Sanjay ; Venter, Henrietta ; Powell, Andrew ; White, Karen ; Petrovski, Kiro R. ; Laven-Law, Geraldine ; Tótoli, Eliane G. ; Salgado, Hérida R. ; Pi, Hongfei ; Coombs, Geoffrey W. ; Shinabarger, Dean L. ; Turnidge, John D. ; Paton, James C. ; McCluskey, Adam ; Trott, Darren J. / Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent. In: PLoS ONE. 2017 ; Vol. 12, No. 9.
@article{d5d6a0be1d5846be9647867c5f60d7dc,
title = "Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent",
abstract = "The spread of multidrug resistance among bacterial pathogens poses a serious threat to public health worldwide. Recent approaches towards combating antimicrobial resistance include repurposing old compounds with known safety and development pathways as new antibacterial classes with novel mechanisms of action. Here we show that an analog of the anticoccidial drug robenidine (4,6-bis(2-((E)-4-methylbenzylidene)hydrazinyl)pyrimidin-2-amine; NCL195) displays potent bactericidal activity against Streptococcus pneumoniae and Staphylococcus aureus by disrupting the cell membrane potential. NCL195 was less cytotoxic to mammalian cell lines than the parent compound, showed low metabolic degradation rates by human and mouse liver microsomes, and exhibited high plasma concentration and low plasma clearance rates in mice. NCL195 was bactericidal against Acinetobacter spp and Neisseria meningitidis and also demonstrated potent activity against A. baumannii, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Enterobacter spp. in the presence of sub-inhibitory concentrations of ethylenediaminetetra-acetic acid (EDTA) and polymyxin B. These findings demonstrate that NCL195 represents a new chemical lead for further medicinal chemistry and pharmaceutical development to enhance potency, solubility and selectivity against serious bacterial pathogens.",
author = "Ogunniyi, {Abiodun D.} and Manouchehr Khazandi and Stevens, {Andrew J.} and Sims, {Sarah K.} and Page, {Stephen W.} and Sanjay Garg and Henrietta Venter and Andrew Powell and Karen White and Petrovski, {Kiro R.} and Geraldine Laven-Law and T{\'o}toli, {Eliane G.} and Salgado, {H{\'e}rida R.} and Hongfei Pi and Coombs, {Geoffrey W.} and Shinabarger, {Dean L.} and Turnidge, {John D.} and Paton, {James C.} and Adam McCluskey and Trott, {Darren J.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1371/journal.pone.0183457",
language = "English",
volume = "12",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

Ogunniyi, AD, Khazandi, M, Stevens, AJ, Sims, SK, Page, SW, Garg, S, Venter, H, Powell, A, White, K, Petrovski, KR, Laven-Law, G, Tótoli, EG, Salgado, HR, Pi, H, Coombs, GW, Shinabarger, DL, Turnidge, JD, Paton, JC, McCluskey, A & Trott, DJ 2017, 'Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent' PLoS ONE, vol. 12, no. 9, e0183457. https://doi.org/10.1371/journal.pone.0183457

Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent. / Ogunniyi, Abiodun D.; Khazandi, Manouchehr; Stevens, Andrew J.; Sims, Sarah K.; Page, Stephen W.; Garg, Sanjay; Venter, Henrietta; Powell, Andrew; White, Karen; Petrovski, Kiro R.; Laven-Law, Geraldine; Tótoli, Eliane G.; Salgado, Hérida R.; Pi, Hongfei; Coombs, Geoffrey W.; Shinabarger, Dean L.; Turnidge, John D.; Paton, James C.; McCluskey, Adam; Trott, Darren J.

In: PLoS ONE, Vol. 12, No. 9, e0183457, 01.09.2017.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent

AU - Ogunniyi, Abiodun D.

AU - Khazandi, Manouchehr

AU - Stevens, Andrew J.

AU - Sims, Sarah K.

AU - Page, Stephen W.

AU - Garg, Sanjay

AU - Venter, Henrietta

AU - Powell, Andrew

AU - White, Karen

AU - Petrovski, Kiro R.

AU - Laven-Law, Geraldine

AU - Tótoli, Eliane G.

AU - Salgado, Hérida R.

AU - Pi, Hongfei

AU - Coombs, Geoffrey W.

AU - Shinabarger, Dean L.

AU - Turnidge, John D.

AU - Paton, James C.

AU - McCluskey, Adam

AU - Trott, Darren J.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - The spread of multidrug resistance among bacterial pathogens poses a serious threat to public health worldwide. Recent approaches towards combating antimicrobial resistance include repurposing old compounds with known safety and development pathways as new antibacterial classes with novel mechanisms of action. Here we show that an analog of the anticoccidial drug robenidine (4,6-bis(2-((E)-4-methylbenzylidene)hydrazinyl)pyrimidin-2-amine; NCL195) displays potent bactericidal activity against Streptococcus pneumoniae and Staphylococcus aureus by disrupting the cell membrane potential. NCL195 was less cytotoxic to mammalian cell lines than the parent compound, showed low metabolic degradation rates by human and mouse liver microsomes, and exhibited high plasma concentration and low plasma clearance rates in mice. NCL195 was bactericidal against Acinetobacter spp and Neisseria meningitidis and also demonstrated potent activity against A. baumannii, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Enterobacter spp. in the presence of sub-inhibitory concentrations of ethylenediaminetetra-acetic acid (EDTA) and polymyxin B. These findings demonstrate that NCL195 represents a new chemical lead for further medicinal chemistry and pharmaceutical development to enhance potency, solubility and selectivity against serious bacterial pathogens.

AB - The spread of multidrug resistance among bacterial pathogens poses a serious threat to public health worldwide. Recent approaches towards combating antimicrobial resistance include repurposing old compounds with known safety and development pathways as new antibacterial classes with novel mechanisms of action. Here we show that an analog of the anticoccidial drug robenidine (4,6-bis(2-((E)-4-methylbenzylidene)hydrazinyl)pyrimidin-2-amine; NCL195) displays potent bactericidal activity against Streptococcus pneumoniae and Staphylococcus aureus by disrupting the cell membrane potential. NCL195 was less cytotoxic to mammalian cell lines than the parent compound, showed low metabolic degradation rates by human and mouse liver microsomes, and exhibited high plasma concentration and low plasma clearance rates in mice. NCL195 was bactericidal against Acinetobacter spp and Neisseria meningitidis and also demonstrated potent activity against A. baumannii, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Enterobacter spp. in the presence of sub-inhibitory concentrations of ethylenediaminetetra-acetic acid (EDTA) and polymyxin B. These findings demonstrate that NCL195 represents a new chemical lead for further medicinal chemistry and pharmaceutical development to enhance potency, solubility and selectivity against serious bacterial pathogens.

UR - http://www.scopus.com/inward/record.url?scp=85029216832&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0183457

DO - 10.1371/journal.pone.0183457

M3 - Article

VL - 12

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 9

M1 - e0183457

ER -

Ogunniyi AD, Khazandi M, Stevens AJ, Sims SK, Page SW, Garg S et al. Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent. PLoS ONE. 2017 Sep 1;12(9). e0183457. https://doi.org/10.1371/journal.pone.0183457